ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP reminded investors of a class action lawsuit against ADMA Biologics alleging violations of §§10(b) and 20(a). The notice is legal-risk negative for the stock, but the article provides no specific financial impact, settlement, or company response.

Analysis

Schall, Brown & Schwartz LLP reminded investors of a class action lawsuit against ADMA Biologics alleging violations of §§10(b) and 20(a). The notice is legal-risk negative for the stock, but the article provides no specific financial impact, settlement, or company response.